Agilent Technologies (A)
(Delayed Data from NYSE)
$142.92 USD
+0.39 (0.27%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $142.86 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$142.92 USD
+0.39 (0.27%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $142.86 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
Agilent (A) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Agilent (A) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
by Zacks Equity Research
Agilent's (A) fiscal third-quarter results reflect weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.
Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilent Technologies (A) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Agilent (A) delivered earnings and revenue surprises of 5.60% and 0.99%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilent (A) Boosts LSAG Segment With J&W 5Q GC/MS Columns
by Zacks Equity Research
Agilent Technologies (A) launches J&W 5Q GC/MS Columns to address the growing demand for modern laboratories.
Agilent (A) Set to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Agilent's (A) fiscal third-quarter results are likely to reflect strength in the ACG and DGG segments despite the weak LSAG segment.
Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2024.
Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ametek (AME) Beats Q2 Earnings Estimates
by Zacks Equity Research
Ametek (AME) delivered earnings and revenue surprises of 1.22% and 2.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cognex Corporation (CGNX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cognex (CGNX) delivered earnings and revenue surprises of 15% and 2.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System
by Zacks Equity Research
Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.
Why Is Agilent (A) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for June 7th
by Zacks Equity Research
A, CAR and BGS have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2024.
Agilent (A) Boosts Reach to Lab Researchers With New Devices
by Zacks Equity Research
Agilent (A) boosts its presence in the mass spectrometry market with the launch of the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell.
Waters (WAT) Expands Mass Spectrometer Portfolio With Xevo MRT
by Zacks Equity Research
Waters (WAT) boosts MS offerings with the launch of Xevo MRT, strengthening its Waters operating segment's portfolio.
Investing in Agilent (A)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Examine the evolution of Agilent's (A) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Agilent (A) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Agilent's (A) fiscal second-quarter results reflect weak momentum across all end markets.
Agilent (A) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilent Technologies (A) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Agilent (A) delivered earnings and revenue surprises of 2.52% and 0.46%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilent (A) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Agilent Technologies' (A) second-quarter fiscal 2024 results are likely to reflect solid momentum across the ACG & DGG segments amid softness in the LSAG segment.
Agilent (A) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Agilent (A) for the quarter ended April 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PDD Holdings (PDD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PDD Holdings' (PDD) first-quarter results are expected to reflect solid momentum in the agriculture business.
Intuit (INTU) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Intuit's (INTU) third-quarter fiscal 2024 results are expected to reflect strength in Online Ecosystem revenues, driven by the launch of QuickBooks Solopreneur.
What's in the Offing for Analog Devices (ADI) in Q2 Earnings?
by Zacks Equity Research
Analog Devices' (ADI) performance in second-quarter fiscal 2024 is likely to have been affected by softness in the industrial, consumer and communication markets.